Table 1.
Correlation between Par3, Par6β, and PKCζ Immunohistochemical Expressions and Clinicopathologic Factors in CRAC Patients (n = 393)
| Characteristics | Patients No. (%) | Par3 |
Patients No. (%) | Par6β |
Patients No. (%) | PKCζ |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | P | Low | High | P | Low | High | P | ||||
| Sex | .643 | .629 | .664 | |||||||||
| Male | 215 (57) | 166 (58) | 49 (55) | 222 (57) | 147 (58) | 75 (56) | 217 (57) | 130 (57) | 87 (59) | |||
| Female | 161 (43) | 121 (42) | 40 (45) | 166 (43) | 106 (42) | 60 (44) | 161 (43) | 100 (44) | 61 (41) | |||
| Age, years (mean) | 393 | 58 | 60 | .594 | 393 | 58 | 60 | .691 | 393 | 59 | 59 | .441 |
| Pathologic stage | .499 | .381 | .028 | |||||||||
| I-II | 189 (51) | 141 (50) | 48 (54) | 196 (51) | 123 (49) | 73 (54) | 191 (51) | 105 (47) | 86 (58) | |||
| III-IV | 183 (49) | 142 (52) | 41 (46) | 188 (49) | 126 (51) | 62 (46) | 183 (49) | 121 (54) | 62 (42) | |||
| Differentiation | .043 | .608 | .408 | |||||||||
| WD | 85 (23) | 58 (20) | 27 (31) | 89 (23) | 56 (22) | 33 (25) | 86 (23) | 49 (22) | 37 (25) | |||
| MD + PD | 288 (77) | 227 (80) | 61 (69) | 296 (77) | 195 (78) | 101 (75) | 289 (77) | 179 (79) | 110 (75) | |||
| LN metastasis | .217 | .552 | .039 | |||||||||
| Absent | 207 (56) | 153 (54) | 54 (61) | 214 (56) | 136 (55) | 78 (58) | 208 (51) | 116 (51) | 92 (62) | |||
| Present | 165 (44) | 131 (46) | 34 (39) | 170 (44) | 113 (45) | 57 (42) | 166 (49) | 110 (49) | 56 (38) | |||
| Ki67 index | .000 | .853 | .863 | |||||||||
| Low | 223 (62) | 157 (57) | 69 (79) | 232 (63) | 149 (63) | 83 (64) | 224 (62) | 134 (62) | 90 (63) | |||
| High | 135 (88) | 117 (43) | 18 (21) | 1358 (37) | 88 (37) | 47 (36) | 135 (38) | 82 (38) | 53 (37) |
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; LN, lymph node.